TNG260是一种小分子CoREST抑制剂,可使STK11突变瘤对抗PD-1免疫疗法产生敏感性
Leanne G Ahronian1, Soumyadip Sahu2, Minjie Zhang3
1Tango Therapeutics (United States), Boston, MA, United States.
Cancer research
|August 29, 2025
概括
具有STK11突变的非小细胞肺癌 (NSCLC) 对抗PD-1治疗具有抗药性. 在临床前和临床研究中,用TNG260向HDAC1可以逆转这种抗药性,从而增强抗PD-1的疗效.
科学领域:
- 癌症学
- 免疫疗法
- 分子生物学
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,STK11的丧失会对抗PD-1等免疫检查点抑制剂 (ICI) 产生抗药性.
- 确定新的治疗点对于克服STK11突变NSCLC中的ICI耐药性至关重要.
研究的目的:
- 确定可以逆转STK11损失驱动的抗PD-1治疗的标.
- 开发和评估一种针对COREST复合物的新疗法TNG260.
主要方法:
- 进行了体内CRISPR选,以确定逆转抗PD-1的标.
- 开发了 CoREST 复合物的小分子抑制剂 TNG260.
- 在临床前NSCLC模型和1期临床试验中评估了TNG260与抗PD-1的结合 (NCT05887492).
主要成果:
- HDAC1被确定为克服STK11损失介导的抗PD-1耐药性的关键目标.
- 在STK11缺乏的癌细胞中,TNG260对CoREST复合体进行了强有力的选择性抑制,增加了免疫调节基因表达.
- 在临床前模型中,使用TNG260和抗PD-1的联合治疗诱导了瘤静止/回归,并显示了患者瘤中素乙化,PD- L1表达和T细胞透的增加.
结论:
- 用TNG260向HDAC1代表了对STK11突变NSCLC对抗PD-1疗法的重新敏感化的有希望的策略.
- 通过调节瘤微环境,TNG260与抗PD-1的组合增强了抗瘤免疫力.
- 这种方法为通常对当前免疫疗法反应不佳的STK11突变NSCLC患者提供了潜在的新治疗途径.
更多相关视频
相关概念视频
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K


